NASDAQ:ABVX Abivax Q4 2025 Earnings Report $139.90 -0.84 (-0.60%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$139.00 -0.90 (-0.64%) As of 07/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Abivax EPS ResultsActual EPS-$1.20Consensus EPS -$2.24Beat/MissBeat by +$1.04One Year Ago EPSN/AAbivax Revenue ResultsActual Revenue$0.52 millionExpected Revenue$1.80 millionBeat/MissMissed by -$1.28 millionYoY Revenue GrowthN/AAbivax Announcement DetailsQuarterQ4 2025Date3/23/2026TimeBefore Market OpensConference Call DateMonday, March 23, 2026Conference Call Time7:00AM ETUpcoming EarningsAbivax's Q2 2026 earnings is estimated for Monday, September 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) Abivax Earnings HeadlinesAbivax CEO says $920M raise funds U.S. drug launch without Big PharmaJuly 10 at 12:39 PM | finance.yahoo.comAbivax SA Sponsored ADR (ABVX) Gets a Hold from WedbushJuly 10 at 7:39 AM | theglobeandmail.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.July 11 at 1:00 AM | Investors Alley (Ad)Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBCJuly 10 at 6:10 AM | cnbc.comAbivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 8 at 2:14 AM | americanbankingnews.comAbivax Announces Closing of $920 Million Public OfferingJuly 6, 2026 | globenewswire.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxFounded in 2013 and headquartered in Paris, France, Abivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B. With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide. View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Why WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real ProfitLockheed Martin Secures the Ultimate Defense Moat Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
